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Background:  The  most  advanced  dengue  vaccine  candidate  is  a live-attenuated  recombinant  vaccine  con-
taining the  four  dengue  viruses  on  the  yellow  fever  vaccine  backbone  (CYD-TDV)  developed  by  Sanoﬁ
Pasteur.  Several  analyses  have  been  published  on  the  safety  and  immunogenicity  of  the  CYD-TDV  vaccine
from single  trials  but  none  modelled  the heterogeneity  observed  in the  antibody  responses  elicited  by
the  vaccine.
Methods:  We  analyse  the immunogenicity  data  collected  in  ﬁve  phase-2  trials  of the  CYD-TDV  vaccine.  We
provide  a descriptive  analysis  of the  aggregated  datasets  and  ﬁt  the  observed  post-vaccination  PRNT50
titres  against  the  four  dengue  (DENV)  serotypes  using  multivariate  regression  models.
Results:  We  ﬁnd  that  the  responses  to  CYD-TDV  are  principally  predicted  by  the  baseline  immunological
status  against  DENV,  but  the trial  is  also  a signiﬁcant  predictor.  We  ﬁnd  that  the  CYD-TDV  vaccine  gen-
erates  similar  titres  against  all  serotypes  following  the  third  dose,  though  DENV4  is  immunodominant
after the ﬁrst  dose.
Conclusions:  This  study  contributes  to a better  understanding  of the  immunological  responses  elicited
by CYD-TDV.  The  recent  availability  of phase-3  data  is a unique  opportunity  to further  investigate  the
immunogenicity  and efﬁcacy  of the  CYD-TDV  vaccine,  especially  in  subjects  with  different  levels  of  pre-
existing  immunity  against  DENV.
Modelling  multiple  immunological  outcomes  with  a single  multivariate  model  offers  advantages  over
traditional  approaches,  capturing  correlations  between  response  variables,  and  the statistical  method
adopted  in this  study  can  be  applied  to a variety  of  infections  with  interacting  strains.
ublis©  2015  The  Authors.  P
. Introduction
Dengue is a systemic vector-borne viral infection caused by
our distinct virus serotypes (DENV1–4) which are transmitted
y Aedes mosquitoes. Recent estimates suggest that worldwide,
engue infects 390 million people annually [1] and that more than
alf of the world’s population is at risk of dengue infection [2].
urrently, there is no antiviral treatment, so future hopes for con-
rol rely on the development of an effective dengue vaccine [2,3]
nd on improved vector control [4,5]. The most advanced dengue
accine candidate (CYD-TDV) is a recombinant, live-attenuated,
∗ Corresponding author. Tel.: +44 20 7594 3229.
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
tetravalent vaccine constructed on the Yellow Fever Vaccine (YFV)
17D backbone. Several descriptive analyses have been published
on the safety and immunogenicity of CYD-TDV using data from
single trials [6–12] but none of these studies modelled the hetero-
geneity observed in the antibody responses elicited by the vaccine.
Moreover, the ﬁrst phase-2b efﬁcacy trial [9] suggested that efﬁcacy
varied by serotype, with no statistically signiﬁcant efﬁcacy against
DENV2 observed.
In this work we analyse the immunogenicity data collected
in ﬁve phase-2, randomised, observer-blind, controlled trials of
the CYD-TDV dengue vaccine [6,9–12]. Using multivariate regres-
sion models we identify the factors which best reproduce the
heterogeneity in antibody responses among vaccine recipients
and simultaneously estimate the correlations between antibody
responses generated to the four serotypes. The application of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ultivariate regression models is novel in the ﬁeld of immuno-
enicity modelling. This analysis contributes to a better under-
tanding of the immune response conferred by CYD-TDV and assists
n the biological interpretation of the phase-3 efﬁcacy results.
. Methods
.1. Data
We  analyse the immunogenicity data collected in the vaccine
rm of ﬁve phase-2, randomised, observer-blind, controlled trials
f CYD-TDV conducted in the Philippines [10], Latin America [12],
ietnam [6], Thailand [9] and Brazil [11]. The subjects enrolled
n the trials were randomized with a 2:1 ratio to receive vaccine
r placebo, respectively. Vaccine was delivered as three subcu-
aneous injections at months 0, 6 and 12. Blood samples for the
ssessment of the immunogenicity properties of CYD-TDV were
btained before the ﬁrst dose and 28 days after each dose from
ll subjects in the Philippines, Latin America, Vietnam and Brazil
nd on a subset of 300 subjects in Thailand. Serum levels of neu-
ralizing antibodies against each of the four CYD-TDV’s dengue
arental strains were determined using the 50% plaque reduction
eutralizing test (PRNT50) [13]. The blood samples collected at
aseline in the Philippines, Vietnam and Thailand were also tested
ith PRNT50 to assess Japanese encephalitis virus (JEV) seropos-
tivity. The blood samples collected in Latin America were tested
or Yellow fever virus (YFV) but due to recently suspected cross
eactivity with dengue using the current assay we did not use
he YFV seropositivity results in this analysis. The lower limit of
uantitation of the DENV and JEV PRNT50 was 10 (1/dil) and sam-
les with titre ≥ 10 were considered seropositive (DENV+, JEV+).
e deﬁned a categorical variable describing the DENV immune
tatus at baseline. Following [14], subjects were deﬁned seroneg-
tive (DENV−)  if the titres against all four DENV serotypes were
elow 10. Subjects who were DENV seropositive at baseline were
lassed as having monotypic titre proﬁles if they had only one
erotype titre ≥ 10 or more than one serotype ≥10 with a titre ≥ 80
o only one serotype and as having a multitypic proﬁle if they had
itres ≥ 10 to more than one serotype without titre ≥ 80 to only one
erotype. Sensitivity analysis on the deﬁnitions of the DENV and
EV immune status is presented in the Supplementary information
SI).
.2. Analysis
Initially we selected all CYD-TDV recipients with complete
ecords of baseline (B), post-dose 1 (PD1), post-dose 2 (PD2) and
ost-dose 3 (PD3) titres against the four dengue serotypes and with
aseline titres against YFV or JEV (see Table 1). We then examined
he distribution of titres and increases in titre after each dose as a
unction of baseline DENV and JEV immune status.
We then developed multivariate regression models to predict
D3 titres using only information available at baseline. Table S1
etails the subjects included in this analysis. The predictors con-
idered in our analysis were: baseline titres against DENV1–4 and
EV, baseline immunological status to DENV and JEV, gender, age,
rial code and trial location (see Table S2). We  denote the log 10 of
he PD3 titre of subject j (j = 1, ..., n) against DENV i (i = 1, ..., 4) as
ji and the observed kth covariate for subject j (k = 1, ..., p) as Wjk.
e then model the PD3 titres using multivariate linear regression
odels, deﬁned byji =
p∑
k=0
Wjkˇki + eji (1)3 (2015) 3746–3751 3747
where Wj0 = 1 corresponds to an intercept, ˇki are the coefﬁcients
of the covariates and eji is the residual error of subject j against
DENV serotype i. We  assume that the errors eji are jointly normal
with mean zero and that Cov
(
eji, ehl
)
= 0 for different individuals
j and h (i.e. individuals are independent) and Cov
(
eji, ejl
)
= ˙il for
serotypes i and l (i.e. responses to the four DENV serotypes are
correlated and the variance-covariance matrix  ˙ is the same for
all subjects). We  estimate the coefﬁcients ˇki and the variance-
covariance terms ˙il by maximum likelihood and adopt the Akaike
Information Criterion (AIC) for model selection and compari-
son. The AIC is deﬁned as AIC = 2np − 2 ln (L), where np denotes
the number of parameters and L denotes the maximized like-
lihood. Models with an AIC difference from the best model
AICi = AICi − AICmin ≥ 4 are considered to have signiﬁcantly less
support than the best model [15].
We initially deﬁne 11 incrementally more sophisticated mod-
els using the baseline DENV antibody titres as predictors of the
PD3 DENV titres. Model 1 predicts the PD3 titres using the homol-
ogous baseline titres. Models 2 and 3 extend model 1 by including
the maximum or average of the heterologous baseline titres,
respectively. Models 4 and 5 use all four serotype antibody titres
(homologous and heterologous) as covariates; in model 4 only
the coefﬁcient of the homologous titre varies with the serotype
response being predicted whilst in model 5 we  additionally allow
the coefﬁcients of the heterologous baseline titres to vary with the
response’s serotype. Models 6–11 extend models 1–5 by including
interactions between different serotype titres. We then progres-
sively build on the two best ﬁtting of these 11 model variants
and increase complexity by successively adding each one of the
remaining covariates (baseline immunological status to DENV and
JEV; gender; age; trial code; trial location; baseline titre against
JEV). All model variants are described in the SI (Section 1.4). More-
over, we  tested the predictive power of the best models using
cross-validation (Section 2.3 of the SI). The analysis was  performed
using MATLAB (release R2013b) and R (version 3.0.2).
3. Results
A total number of 867 subjects in the vaccine group had com-
plete records of baseline, PD1, PD2 and PD3 titres against the four
dengue serotypes and baseline titres against JEV. Details on the
baseline demographic and immunological characteristics of the
subjects included in the analysis are given in Table 1.
Fig. 1 shows the mean and 95% conﬁdence interval (CI) of the
DENV titre measurements and the rises in titres observed after each
vaccination, stratiﬁed by the baseline DENV immunological status
of the subjects (i.e. DENV seronegative, monotypic or multitypic
proﬁle). Subjects with multitypic baseline DENV status developed
signiﬁcantly higher DENV titres (at PD1, PD2 and PD3 measure-
ments) than subjects who  had a seronegative or monotypic baseline
DENV immune status. Subjects with monotypic proﬁle at baseline
showed PD3 titres in between DENV seronegative and multitypic
subjects. Fig. 1 also shows that the observed rises in titres var-
ied by serotype and similar trends were observed having stratiﬁed
the baseline monotypic subjects into subclasses, according to the
(presumed) infecting serotype (Figs. S2 and S3).
Figs. S4 and S5, respectively, show DENV titres and rises in
titres after each dose, stratiﬁed by baseline DENV immunologi-
cal status and continent of enrolment (i.e. Southeast Asia or Latin
America), trial and JEV status. We  observe (Fig. S4) that Latin Amer-
ican DENV seropositive subjects had signiﬁcantly higher DENV1–4
titres (both pre-vaccination and at all measurement time points
post-vaccination) than Southeast Asian DENV seropositive sub-
jects. Moreover, within the group of subjects who were DENV
seropositive at baseline, subjects who  were also seropositive to JEV
3748 I. Dorigatti et al. / Vaccine 33 (2015) 3746–3751
Table 1
Baseline demographic characteristics of the subjects included in the descriptive analysis.
Study Location Age (years) N Females JEV+ DENV− DENV+ monotypic DENV+ multitypic
T1 Philippines 1.1 (1.0, 1.2) 116 53 (46%) 6 (5%) 61 (53%) 44 (38%) 11 (9%)
T2  Latin America 12.6 (9.4, 16.2) 361 187 (52%) – 91 (25%) 55 (15%) 215 (60%)
T3  Vietnam 10.8 (3.1, 28.3) 113 59 (52%) 42 (37%) 34 (30%) 37 (33%) 42 (37%)
T4  Thailand 8.3 (4.9, 11.0) 188 108 (57%) 151 (80%) 55 (29%) 51 (27%) 82 (44%)
T5  Brazil 12.7 (9.3, 16.3) 89 52 (58%) – 26 (29%) 14 (16%) 49 (55%)
Note: Study denotes the trail identiﬁer; Location denotes the location where the trial was conducted, i.e. the country if the trial was single-site or the region if the trial was
multicentre; Age denotes the observed mean and 5–95 percentiles of the age of the subjects included in the analysis in years; N denotes the number of subjects; JEV+ denotes
subjects  with titre against JEV ≥ 10; DENV− denotes subjects with titres < 10 for all four DENV serotypes; DENV+ denotes subjects with titres ≥ 10 for at least one DENV
serotype; monotypic denotes subjects with titres ≥ 10 for one DENV serotype only or more than one DENV serotype with a titre ≥ 80 to only one DENV serotype; multitypic
denotes subjects with titres ≥ 10 for at least two DENV serotypes without titre ≥ 80 to only one DENV serotype. The percentages within parentheses are computed on the
number of subjects in each study (N). All titres have been quantiﬁed using PRNT50.
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columns) by baseline immunological status against DENV (colour code). Undetect
hown  on a log 10 scale. Increases in titres are shown on a log 2 scale, according to 
howed higher DENV1–4 titres than JEV seronegative subjects. Figs.
4 and S5 also illustrate the substantial variability in DENV titres
nd increases in titres observed between trials.
Fig, 2 shows pairwise scatterplots of the observed PD3 DENV
itres by serotype, stratiﬁed by the baseline immunological sta-
us against DENV. The PD3 titres of the subjects with multitypic
mmunological proﬁles at baseline tend to cluster in the top right
egion of the plane, where the titres against both serotypes are
igh, those of seronegative subjects at baseline tend to cluster
n the lower region of the plane, where the titres against both
erotypes are low and the PD3 titres of monotypic proﬁles at
aseline scatter in-between the two aforementioned clusters. The
orrelation observed in the PD3 titres against DENV1–4 (Fig. 2)
ogether with the joint normality of the data (Fig. S1) supports the
hoice of a multivariate normal regression model [16].
From the analysis of regression models 1–11 (Table S3) we  ﬁnd
hat models including all (homologous and heterologous) base-
ine DENV titres (models 4 and 5) ﬁt the data signiﬁcantly better
han models which use the homologous baseline titre as the only
redictor (model 1) or which include a summary statistic of the
eterologous titres (models 2 and 3). The addition of interaction
erms between the homologous titre and either all heterologous
itres or their average or their maximum further improves the ﬁt
nd we ﬁnd that the two best ﬁtting models by AIC (models 9 andd post-dose 3 (PD3) titres (row 1) and rises in titres (row 2) for each DENV serotype
tres (below the detection threshold of 10) are assigned a titre value of 5. Titres are
ﬁnition.
11) are obtained by adding an interaction between the homologous
titre and the maximum of the heterologous titres to model vari-
ants 4 and 5 (Table 2). Tables S4 and S7 show the results of the two
best ﬁtting models, having successively added one, two and three
additional covariates. We  ﬁnd that adding a trial-speciﬁc intercept
produces the biggest improvement in terms of AIC and explained
variance; adding further information on the baseline DENV status
produces the second largest improvement in AIC whilst adding the
remaining covariates (gender, age, JEV immunological status and
JEV titre) does not produce a substantial improvement in model
ﬁt (AIC < 4) (Tables S4 and S7). The best models overall, denoted
models 9j and 11j, predict the PD3 titres using all (homologous and
heterologous) baseline titres, the interaction between the homolo-
gous and the maximum of the heterologous titres and include trial-
and DENV status-speciﬁc intercepts (see Eqs. (13) and (15) in the SI).
Table 2 summarises the goodness of ﬁt obtained with the most rep-
resentative model variants explored in the multivariate regression
analysis.
Fig. 3 shows the ﬁt of model 9j to the observed PD3 titres as func-
tion of the homologous baseline titre. The expected average titre
predictions across all subjects are obtained using the maximum
likelihood parameter estimates for model 9j (Table S5). To obtain
the model’s predictions with noise (in green in Fig. 3), for each
subject we  simulated 100 independent realizations of the error
I. Dorigatti et al. / Vaccine 33 (2015) 3746–3751 3749
Fig. 2. Scatterplots of post-dose 3 (PD3) titres against heterologous serotypes. Each point represents an observation and the colour of the point denotes the baseline
immunological status against DENV. “DENV−” denotes DENV seronegative (i.e. baseline PRNT50 titres < 10 for all DENV serotypes), “monotypic” denotes subjects with
PRNT50  titres ≥ 10 for one DENV serotype only or more than one DENV serotype with a titre ≥ 80 to only one DENV serotype, “multitypic” denotes subjects with PRNT50
titres  ≥ 10 for at least two DENV serotypes without titre ≥ 80 to only one DENV serotype. Undetectable titres (below the detection threshold of 10) are assigned a titre value
of  5. Titres are shown on a log 10 scale.
Table 2
Summary measures of goodness of ﬁt of selected model variants.
Model Covariates AIC Log-like np R21 R
2
2 R
2
3 R
2
4
1 Xji 4440.73 −2198.36 22 0.53 0.48 0.43 0.21
4  Xj1, ..., Xj4 4374.07 −2157.03 30 0.55 0.50 0.45 0.24
5  Xj1, ..., Xj4 4371.75 −2139.88 46 0.55 0.51 0.46 0.24
9  Xj1, ..., Xj4, Xji × max
k /=  i
Xjk 4350.62 −2137.31 38 0.56 0.51 0.46 0.25
11  Xj1, ..., Xj4, Xji × max
k /=  i
Xjk 4351.85 −2125.92 50 0.56 0.51 0.46 0.24
9g  Xj1, ..., Xj4, Xji × max
k /=  i
Xjk, Tnj 4184.91 −2038.45 54 0.58 0.52 0.50 0.31
11g  Xj1, ..., Xj4, Xji × max
k /=  i
Xjk, Tnj 4181.09 −2024.54 66 0.59 0.52 0.50 0.31
9j  Xj1, ..., Xj4, Xji × max
k /=  i
Xjk, Tnj, Pj 4180.14 −2023.07 58 0.59 0.52 0.50 0.31
11j  Xj1, ..., Xj4, Xji × max
k /=  i
Xjk, Tnj, Pj 4179.74 −2019.87 70 0.59 0.52 0.50 0.31
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Dote: Akaike’s Information Criterion (AIC), log-likelihood (Log-like), number of par
aseline titre of subject j to DENV serotype i; Tnj denotes the trial identiﬁer, i.e. T1j ,
j = [ej1, ej2, ej3, ej4] from a multivariate normal distribution with
ean zero and the estimated variance-covariance matrix, and then
dded the simulated noise to the central prediction for that subject.
ig. 3 and Fig. S6 show that model 9j not only matches the average
esponses but also reproduces the variability observed in the data.
The parameter estimates obtained with models 9j and 11j
Tables S5 and S8) show that the PD3 titres are signiﬁcantly posi-
ively associated with the homologous baseline titre. We  also ﬁnd
 signiﬁcant negative association between the PD3 titre against
ENV1–3 and the baseline titre against DENV4 (see estimates of
2i and ˇ3i in Table S5 and of ˇ3i and ˇ7i in Table S8). PD3 titres
re negatively associated with the interaction term between the
omologous and maximum of the heterologous titres (see esti-
ates of ˇ4i in Table S5 and of ˇ8i in Table S8), which implies that
f the homologous titre or the maximum of the heterologous titres
or both) are high at baseline then the increase in titre induced by
accination is decreased (reﬂecting either saturation in the level of
itres that can be attained or lack of infectivity of CYD-TDV due to
re-existing antibodies). Furthermore, our analysis suggests that
ENV4 titre responses to vaccination are the least correlated withrs (np), fraction of explained variance for serotype i (R2
i
). Xji represents the log 10
3j , T4j , T5j; Pj denotes whether subject j is seropositive to a single DENV serotype.
other serotypes, with an estimated correlation with DENV1–3 of
about 0.4; the correlation between the PD3 titres to DENV1 and
DENV3 is 0.57, and to DENV1 and DENV2 and to DENV2 and DENV3
is 0.52 (Tables S6 and S9).
We  assess the predictive power of the best ﬁt models using a
2-fold cross-validation approach, and ﬁnd that they each explain
at least 57%, 50%, 48% and 27% of the variance observed in the PD3
titres against DENV1–DENV4, respectively (see Section 2.3 of the SI
for details).
Sensitivity analysis on the deﬁnition of DENV seronegative,
monotypic and multitypic (Section 3.3 of the SI) shows that using
a threshold dilution of 40 instead of 10 to deﬁne seronegativity
shifts the PD3 titres of the subjects with monotypic proﬁles at
baseline upwards (Figs. S7–S12 and S17–S22). Using a threshold
titre of 40 (instead of 10) to classify JEV seropositivity (Figs. S13
and S14) does not perturb the patterns observed in Figs. S4 and S5.
The fact that the best model overall is obtained using the thresh-
old dilution of 40 to deﬁne seronegativity (Table S16) suggests that
there is limited variability in the response to CYD-TDV for titres
below 40.
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itres,  obtained with the best model (model 9j). Titres are shown on a log 10 scale an
itres  at baseline).
. Discussion and conclusions
We  have found that the PRNT50 responses elicited by the
YD-TDV vaccine vary primarily by baseline immunological status
gainst DENV and by trial. The ﬁnal PD3 DENV titres of subjects with
 multitypic immunological proﬁle at baseline are signiﬁcantly
igher than the titres reached by those seronegative or with mono-
ypic baseline proﬁles (Fig. 1), though the increases in titres induced
y vaccination are lowest in baseline multitypic subjects. Presum-
bly B- and T-cell immune memory created by prior infection(s),
esults in different effector responses to vaccination, translating to
ifferent humoural response levels.
We  ﬁnd no evidence of differences in ﬁnal PD3 titres or increases
n titres by gender or age once baseline immunological status is
aken into account.
There is substantial heterogeneity in the DENV titres observed
cross trials and we found that including a trial-speciﬁc inter-
ept to the regression models substantially improved model ﬁt.
he estimates of the regression coefﬁcients associated with tri-
ls T2–T5 signiﬁcantly differ from the estimate associated with
rial T1 (Tables S5 and S8), which may  indicate a potential role
f age-related factors such as maternal antibodies in the immune
esponse elicited by CYD-TDV. However, we can exclude that the
bserved variation was due to lack in standardisation of the PRNT
ssay [17–19] since the PRNT50 assays were performed in a single
aboratory for all trials under validated conditions.
We ﬁnd that subjects enrolled in Latin America show consider-
bly higher titres than subjects recruited in Southeast Asia, both at
aseline and after each vaccine dose (Fig. S4, row 1). Beyond demo-
raphic and genetic factors, previous exposure to YFV could have
ontributed to the higher DENV titres. The positive effect of baseline
mmunity to YFV (following either natural infection or immuniza-
ion) on the titres of neutralizing antibodies against DENV1–4 has
een previously observed in monkeys and humans [20–26]. More-
ver, vaccination with CYD-TDV in YFV pre-immune individuals
ould recall cellular responses against the YFV backbone strain,
hich could assist through a bystander effect on speciﬁc responses
gainst the envelope proteins.
In agreement with [27], we ﬁnd that pre-existing immunity
o JEV also induces a broader and stronger response to CYD-TDVnd 5–95 percentiles of the post-dose 3 (PD3) titres versus the homologous baseline
eline titres are grouped in bins of width 0.5 (the ﬁrst bin representing undetectable
vaccination (Fig. S4, row 3). Cross-reactive JEV-DENV E-speciﬁc
memory B cells could be recalled upon CYD-TDV vaccination, boost-
ing cross-reactive responses measured in dengue PRNT.
Supporting earlier reports [24,28] we  ﬁnd that DENV4 shows the
largest increase in antibody titre of all the serotypes after the ﬁrst
vaccine dose, suggesting immunodominance of this vaccine com-
ponent. DENV4 antibody titres show very limited increases after the
second and third doses (Fig. 1 and Fig. S5), while DENV1–3 titres
increase substantially. However, it is unclear the extent to which
the similar ﬁnal PD3 titres seen reﬂects a balanced homotypic
response to all four serotypes or is affected by cross-reactive hete-
rotypic responses, notably against the immunodominant DENV4
component. Overall, PD3 DENV4 titres thus end up comparable to,
if not a little lower than, titres to the other three serotypes (Fig. 1
and Fig. S4).
We ﬁnd that the rises in DENV titres tend to be inversely pro-
portional to the baseline titres (i.e. the higher the baseline titre,
the lower the increase) and the second and third vaccine doses
do not substantially boost the titres of subjects with a multitypic
immunological proﬁle at baseline (Fig. 1), suggesting that sterilising
immunity has been induced. Similarly, our regression models show
a negative coefﬁcient for the interaction term (between homolo-
gous and heterologous titres) as a predictor of PD3 titres (Tables
S5 and S8); i.e. the presence of high (either homologous or het-
erologous) baseline titres limits vaccine-induced increases in titres.
However, in subjects who  were seronegative at baseline, signiﬁ-
cant increases in titres are seen after the second vaccine dose and
some additional beneﬁt from the third (Fig. 1). This suggests that
CYD-TDV does not induce complete protection in subjects who
were seronegative at baseline, consistent with the efﬁcacy proﬁle
observed in the phase-3 trials [30,31].
We  found that baseline DENV4 titres are signiﬁcantly negatively
associated with PD3 titres against DENV1–3; i.e. the presence of
high DENV4 titres limits the increase in DENV1–3 titres. Inter-
estingly, a similar but reverse association (i.e. the presence of
DENV1 and DENV3 titres limiting the increase in DENV4 titres) was
observed in naturally infected subjects [17]. Serotype dominance
could be a possible and consistent explanation of this negative
association. Consistent with Fig. 2, we  estimate that the PD3 titres
against DENV1–4 are positively correlated with each other, which
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uggests no evidence of competition among the DENV serotypes,
hough DENV4 is the least correlated serotype.
We  have shown that our best ﬁtting multivariate regression
odels can accurately reproduce the distribution of observed post-
accination titres using information collected at baseline (Fig. 3)
nd the good predictive power of these models suggests that they
ould be used for predicting immunological outcomes in future
tudies at a population level.
The statistical approach adopted in this study is novel in the
eld of immunogenicity modelling and can be applied to a vari-
ty of infections with interacting strains. Early results from two
arge-scale phase-3 clinical studies are encouraging [29–31] and
he detailed analysis of the phase-3 data will provide further insight
nto the immunogenicity and efﬁcacy of CYD-TDV, in particular
n subjects with different levels of pre-existing immunity against
ENV, YFV and JEV.
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